department of dermatology, university of michigan, ann

Dermatologist Perceptions of Teledermatology Implementation

& Future Use Post COVID-19 Linda Camaj Deda

University of Michigan Medical School, Ann ArborDepartment of Dermatology, University of Michigan, Ann Arbor

AAD Taskforce Collaborators

Rebecca Goldberg, BSTrilokraj Tejasvi, MBBS, MD

Jules B. Lipoff, MDJonathan Kennedy, BS

Siobhan Arey, MPH, MS, PA-CZachary Hopkins, MD

Ramsay Farah, MDAaron M. Secrest, MD, PhD

George Han, MDJason G. Mathis, MD

Rosie Balk, MAMartha Wojtowycz, PhD

Changes in Teledermatology in Setting of COVID-19 Pandemic

Regulatory Changes from the US Centers for Medicare & Medicaid Services

Parity in reimbursement between in-person and video visits

Removing eligibility and geographic restrictions

Methods

TopicsModes Used Situational Appropriateness Reimbursement Perceived NeedBarriers Anticipated Future Use

In May-June 2020, AAD Task Force Subgroup surveyed AAD members regarding effects of COVID-19 on teledermatology

12,070 practicing US dermatologist members of AAD

5,000 randomly selected

4,356 received the survey

591 completed surveys (13.6% response rate)

➥ 644 non-functioning email addresses

Results

14% 97%Prior COVID-19 During COVID-19

Anticipated personal continued use

70%

Teledermatology Utilization

Anticipated Future of Teledermatology

58%Believed teledermatology

will continue post-pandemic

ResultsAppropriate Utilization

LO, live office visitLV, live video visitSDP, stored digital photography

96%

3%

ResultsBarriers

Technology Issues (39%)

Low Reimbursement (70%)

Malpractice/Liability Concerns (27%)

Government Regulations (23%)

Conclusions➥ Teledermatology is likely here to stay.

➥ There are concerns highlighting the need for supportive reimbursement, regulations, and technological innovation (improved connectivity and functionality of video visit platforms).

➥ Refinement of workflow by patient and visit-type selection will likely improve how teledermatology is perceived by dermatologists.

We hope that this data can inform policy changes to address barriers to use.

Cited SourcesCoates SJ, Kvedar J, Granstein RD. Teledermatology: from historical perspective to emerging techniques of the modern era: part I: history, rationale, and current practice. J Am Acad Dermatol. 2015;72(4):563-574. doi:10.1016/j.jaad.2014.07.061PubMedGoogle ScholarCrossref

Harvey JB, Valenta S, Simpson K, Lyles M, McElligott J. Utilization of outpatient telehealth services in parity and nonparity states 2010-2015. Telemed J E Health. 2019;25(2):132-136. doi:10.1089/tmj.2017.0265PubMedGoogle ScholarCrossref

Lee I, Kovarik C, Tejasvi T, Pizarro M, Lipoff JB. Telehealth: helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation. J Am Acad Dermatol. 2020;82(5):1213-1214. doi:10.1016/j.jaad.2020.03.052PubMedGoogle ScholarCrossref

US Centers for Disease Control and Prevention. Using telehealth to expand access to essential health services during the COVID-19 pandemic. Updated June 10, 2020. Accessed July 18, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/telehealth.html

Perkins S, Cohen JM, Nelson CA, Bunick CG. Teledermatology in the era of COVID-19: experience of an academic department of dermatology. J Am Acad Dermatol. 2020;83(1):e43-e44. doi:10.1016/j.jaad.2020.04.048PubMedGoogle ScholarCrossref

Cited ImagesCenters for Medicare and Medicaid Services logo, 1 April 2014, CMS Branding Guidelines, Centers for Medicare and Medicaid Services. As a work of the U.S. federal government, the image is in the public domain.

The greater coat of arms of the United States of America. Ssolbergj, CC BY-SA 3.0 <https://creativecommons.org/licenses/by-sa/3.0>, via Wikimedia Commons

Stock Photos, Canva (2021)